Annual Cash & Cash Equivalents
$16.35 M
-$2.68 M-14.08%
December 31, 2022
Summary
- As of February 10, 2025, NVIV annual cash & cash equivalents is $16.35 million, with the most recent change of -$2.68 million (-14.08%) on December 31, 2022.
- During the last 3 years, NVIV annual cash & cash equivalents has risen by +$9.75 million (+147.67%).
Performance
NVIV Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$8.58 M
-$2.14 M-19.95%
September 30, 2023
Summary
- As of February 10, 2025, NVIV quarterly cash and cash equivalents is $8.58 million, with the most recent change of -$2.14 million (-19.95%) on September 30, 2023.
- Over the past year, NVIV quarterly cash and cash equivalents has dropped by -$2.02 million (-19.02%).
Performance
NVIV Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NVIV Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -14.1% | -19.0% |
| 3 y3 years | +147.7% | +8.6% |
| 5 y5 years | +26.6% | -56.5% |
NVIV Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -14.1% | at low | -54.9% | at low |
| 5 y | 5-year | -16.1% | -59.6% | -65.4% | -23.1% |
| alltime | all time | -23.8% | -100.0% | -81.3% | -100.0% |
InVivo Therapeutics Holdings Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $8.58 M(-20.0%) |
| Jun 2023 | - | $10.72 M(-18.5%) |
| Mar 2023 | - | $13.15 M(-19.6%) |
| Dec 2022 | $16.35 M(-14.1%) | $16.35 M(+54.3%) |
| Sep 2022 | - | $10.60 M(-18.7%) |
| Jun 2022 | - | $13.03 M(-14.2%) |
| Mar 2022 | - | $15.18 M(-20.3%) |
| Dec 2021 | $19.03 M(-2.4%) | $19.03 M(-9.8%) |
| Sep 2021 | - | $21.10 M(-8.4%) |
| Jun 2021 | - | $23.02 M(-7.0%) |
| Mar 2021 | - | $24.77 M(+27.1%) |
| Dec 2020 | $19.49 M(+195.3%) | $19.49 M(+146.7%) |
| Sep 2020 | - | $7.90 M(-19.6%) |
| Jun 2020 | - | $9.82 M(+6.8%) |
| Mar 2020 | - | $9.20 M(+39.4%) |
| Dec 2019 | $6.60 M(-60.4%) | $6.60 M(-18.9%) |
| Sep 2019 | - | $8.14 M(-17.8%) |
| Jun 2019 | - | $9.90 M(-25.0%) |
| Mar 2019 | - | $13.20 M(-20.8%) |
| Dec 2018 | $16.66 M(+29.0%) | $16.66 M(-15.5%) |
| Sep 2018 | - | $19.71 M(-11.7%) |
| Jun 2018 | - | $22.32 M(+92.2%) |
| Mar 2018 | - | $11.61 M(-10.0%) |
| Dec 2017 | $12.91 M(-39.9%) | $12.91 M(-21.4%) |
| Sep 2017 | - | $16.43 M(+14.7%) |
| Jun 2017 | - | $14.32 M(-0.8%) |
| Mar 2017 | - | $14.44 M(-32.7%) |
| Dec 2016 | $21.46 M(+43.9%) | $21.46 M(-43.0%) |
| Sep 2016 | - | $37.66 M(-9.5%) |
| Jun 2016 | - | $41.63 M(-9.0%) |
| Mar 2016 | - | $45.77 M(+206.7%) |
| Dec 2015 | $14.92 M(+10.9%) | $14.92 M(-32.6%) |
| Sep 2015 | - | $22.15 M(-11.8%) |
| Jun 2015 | - | $25.11 M(+2.4%) |
| Mar 2015 | - | $24.52 M(+82.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | $13.46 M(-3.7%) | $13.46 M(-23.7%) |
| Sep 2014 | - | $17.63 M(-15.4%) |
| Jun 2014 | - | $20.85 M(+111.8%) |
| Mar 2014 | - | $9.85 M(-29.6%) |
| Dec 2013 | $13.98 M(+9.0%) | $13.98 M(-23.7%) |
| Sep 2013 | - | $18.33 M(-17.5%) |
| Jun 2013 | - | $22.23 M(+115.8%) |
| Mar 2013 | - | $10.30 M(-19.7%) |
| Dec 2012 | $12.83 M(+193.9%) | $12.83 M(-17.5%) |
| Sep 2012 | - | $15.55 M(-13.8%) |
| Jun 2012 | - | $18.04 M(-8.0%) |
| Mar 2012 | - | $19.61 M(+349.3%) |
| Dec 2011 | $4.36 M(-51.3%) | $4.36 M(+18.4%) |
| Sep 2011 | - | $3.69 M(-25.7%) |
| Jun 2011 | - | $4.96 M(-27.7%) |
| Mar 2011 | - | $6.86 M(>+9900.0%) |
| Dec 2010 | $8.96 M(>+9900.0%) | - |
| Sep 2010 | - | $18.20 K(-53.2%) |
| Jun 2010 | - | $38.90 K(>+9900.0%) |
| Mar 2010 | - | $0.00(0.0%) |
| Mar 2010 | $0.00(0.0%) | - |
| Dec 2009 | - | $0.00(0.0%) |
| Sep 2009 | - | $0.00(-100.0%) |
| Jun 2009 | - | $10.10 K(>+9900.0%) |
| Mar 2009 | $0.00(-100.0%) | $0.00(0.0%) |
| Dec 2008 | - | $0.00(-100.0%) |
| Sep 2008 | - | $300.00(-94.5%) |
| Jun 2008 | - | $5500.00(-75.4%) |
| Mar 2008 | $22.40 K(+322.6%) | $22.40 K(>+9900.0%) |
| Dec 2007 | - | $200.00(-50.0%) |
| Sep 2007 | - | $400.00(-85.7%) |
| Jun 2007 | - | $2800.00(-47.2%) |
| Mar 2007 | $5300.00(-96.7%) | $5300.00(-80.1%) |
| Dec 2006 | - | $26.60 K(-58.9%) |
| Sep 2006 | - | $64.70 K(-59.7%) |
| Mar 2006 | $160.40 K | $160.40 K |
FAQ
- What is InVivo Therapeutics Holdings annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for InVivo Therapeutics Holdings?
- What is InVivo Therapeutics Holdings annual cash & cash equivalents year-on-year change?
- What is InVivo Therapeutics Holdings quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for InVivo Therapeutics Holdings?
- What is InVivo Therapeutics Holdings quarterly cash and cash equivalents year-on-year change?
What is InVivo Therapeutics Holdings annual cash & cash equivalents?
The current annual cash & cash equivalents of NVIV is $16.35 M
What is the all time high annual cash & cash equivalents for InVivo Therapeutics Holdings?
InVivo Therapeutics Holdings all-time high annual cash & cash equivalents is $21.46 M
What is InVivo Therapeutics Holdings annual cash & cash equivalents year-on-year change?
Over the past year, NVIV annual cash & cash equivalents has changed by -$2.68 M (-14.08%)
What is InVivo Therapeutics Holdings quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NVIV is $8.58 M
What is the all time high quarterly cash and cash equivalents for InVivo Therapeutics Holdings?
InVivo Therapeutics Holdings all-time high quarterly cash and cash equivalents is $45.77 M
What is InVivo Therapeutics Holdings quarterly cash and cash equivalents year-on-year change?
Over the past year, NVIV quarterly cash and cash equivalents has changed by -$2.02 M (-19.02%)